585 related articles for article (PubMed ID: 30124065)
1. Salivary Immunoglobulin A, E, and G4 Levels Specific to Dermatophagoides pteronyssinus in Allergic Rhinitis Patients Treated With Subcutaneous Immunotherapy.
Liu Y; Xing Z; Wang J; Geng C
Am J Rhinol Allergy; 2018 Nov; 32(6):458-464. PubMed ID: 30124065
[TBL] [Abstract][Full Text] [Related]
2. The IgE Blocking Activity Induced by Dermatophagoides pteronyssinus Subcutaneous Immunotherapy Does Not Correlate with Specific IgA but with IgG4 in both Serum and Saliva.
He Y; Liu J; Zhao D; Zhang S; Hao G; Sun Y; Zhong H; Chen H; Würtzen PA; Larsen JN; Lai X
Int Arch Allergy Immunol; 2021; 182(12):1231-1244. PubMed ID: 34280916
[TBL] [Abstract][Full Text] [Related]
3. Clinical Response to Subcutaneous Dermatophagoides pteronyssinus Immunotherapy in Children with Allergic Rhinitis and Asthma Is Independent of Sensitization to Blomia tropicalis Allergens.
Chen S; Zheng Y; Chen B; Zhong H; Liao F; Wang L; Hui SF; Lai X
Int Arch Allergy Immunol; 2019; 178(2):201-210. PubMed ID: 30544116
[TBL] [Abstract][Full Text] [Related]
4. The Functional IgE-Blocking Factor Induced by Allergen-Specific Immunotherapy Correlates with IgG4 Antibodies and a Decrease of Symptoms in House Dust Mite-Allergic Children.
Zhao D; Lai X; Tian M; Jiang Y; Zheng Y; Gjesing B; Zhong N; Spangfort MD
Int Arch Allergy Immunol; 2016; 169(2):113-20. PubMed ID: 27049773
[TBL] [Abstract][Full Text] [Related]
5. Serum and salivary IgE, IgA, and IgG4 antibodies to Dermatophagoides pteronyssinus and its major allergens, Der p1 and Der p2, in allergic and nonallergic children.
Miranda DO; Silva DA; Fernandes JF; Queirós MG; Chiba HF; Ynoue LH; Resende RO; Pena JD; Sung SS; Segundo GR; Taketomi EA
Clin Dev Immunol; 2011; 2011():302739. PubMed ID: 22007250
[TBL] [Abstract][Full Text] [Related]
6. Immunologic alterations and efficacy of subcutaneous immunotherapy with Dermatophagoides pteronyssinus in monosensitized and polysensitized patients.
Soyyigit S; Guloglu D; Ikinciogullari A; Secil D; Oztuna D; Mungan D; Misirligil Z; Sin BA
Ann Allergy Asthma Immunol; 2016 Mar; 116(3):244-251.e2. PubMed ID: 26945497
[TBL] [Abstract][Full Text] [Related]
7. Functional and Immunoreactive Levels of IgG4 Correlate with Clinical Responses during the Maintenance Phase of House Dust Mite Immunotherapy.
Feng M; Su Q; Lai X; Xian M; Shi X; Wurtzen PA; Qin R; Zeng X; Li J
J Immunol; 2018 Jun; 200(12):3897-3904. PubMed ID: 29728509
[TBL] [Abstract][Full Text] [Related]
8. [The impact of subcutaneous immunotherapy with Dermatophagoides farinae and Dermatophagoides pteronyssinus on the quality of life of patients with allergic rhinitis and asthma].
Yepes-Núñez JJ; Gómez C; Espinoza Y; Cardona R
Biomedica; 2014; 34(2):282-90. PubMed ID: 24967933
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of two commercial house dust mite extracts for allergic rhinitis: a head-to-head study.
Li J; Wu Y; Yang Y; Huang N; Li W; Zhang S; Jiang Q; Yang L; Zhu R
Int Forum Allergy Rhinol; 2019 Aug; 9(8):876-882. PubMed ID: 31322838
[TBL] [Abstract][Full Text] [Related]
10. Changes in IL-10 and specific antibodies associated to successful Dermatophagoides pteronyssinus immunotherapy in children during the first year of treatment.
Martín-Muñoz MF; Pineda F; Muiños T; Fontan M; Nevot S; Bosque M; Jurado Palomo J; Torredemer A; Valdesoiro L; Martinez Cañavate AM; Pedemonte Marco C;
Allergol Immunopathol (Madr); 2013; 41(1):4-10. PubMed ID: 22321665
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of D. pteronyssinus immunotherapy in local allergic rhinitis: a double-blind placebo-controlled clinical trial.
Rondón C; Campo P; Salas M; Aranda A; Molina A; González M; Galindo L; Mayorga C; Torres MJ; Blanca M
Allergy; 2016 Jul; 71(7):1057-61. PubMed ID: 27008542
[TBL] [Abstract][Full Text] [Related]
12. Different Responses in Induction of Allergen Specific Immunoglobulin G4 and IgE-Blocking Factors for Three Mite Subcutaneous Immunotherapy Products.
Park KH; Lee SC; Son YW; Jeong KY; Shin YS; Shin JU; Sim da W; Park HJ; Lee JH; Lee KH; Park JW
Yonsei Med J; 2016 Nov; 57(6):1427-34. PubMed ID: 27593871
[TBL] [Abstract][Full Text] [Related]
13. Specific immunoglobulin E and immunoglobulin G4 toward major allergens of house-dust mite during allergen-specific immunotherapy.
Chen J; Zhou Y; Wang Y; Zheng Y; Lai X; Westermann-Clark E; Cho SH; Kong W
Am J Rhinol Allergy; 2017 May; 31(3):156-160. PubMed ID: 28490399
[TBL] [Abstract][Full Text] [Related]
14. Suppression function against environmental dust exposure after Dermatophagoides pteronyssinus immunotherapy is associated with production of specific and cross-reactive immunoglobulin G4.
Feng M; Luo T; Xian M; Shi X; Qin R; Zeng X; Su Q; Li J
Clin Exp Allergy; 2022 Jul; 52(7):878-887. PubMed ID: 34962673
[TBL] [Abstract][Full Text] [Related]
15. Dose-Dependent Immunological Responses after a 6-Month Course of Sublingual House Dust Mite Immunotherapy in Patients with Allergic Rhinitis.
Didier A; Campo P; Moreno F; Durand-Perdriel F; Marin A; Chartier A
Int Arch Allergy Immunol; 2015; 168(3):182-92. PubMed ID: 26789997
[TBL] [Abstract][Full Text] [Related]
16. Immune signatures predict response to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis.
Wang N; Song J; Sun SR; Zhu KZ; Li JX; Wang ZC; Guo CL; Xiang WX; Tong YL; Zeng M; Wang H; Xu XY; Yao Y; Liu Z
Allergy; 2024 May; 79(5):1230-1241. PubMed ID: 38403941
[TBL] [Abstract][Full Text] [Related]
17. Semi-depot house-dust mite allergen extract for Chinese with allergic rhinitis and asthma.
Li X; Wang X; Lin X; Xu G; Tao Z; Jiang W; Cheng L; Guo Y; Lai H; Shen K
Am J Rhinol Allergy; 2016 May; 30(3):201-8. PubMed ID: 27216351
[TBL] [Abstract][Full Text] [Related]
18. A randomized, 5-arm dose finding study with a mite allergoid SCIT in allergic rhinoconjunctivitis patients.
Pfaar O; Nell MJ; Boot JD; Versteeg SA; van Ree R; Roger A; Riechelmann H; Sperl A; Oude Elberink JN; Diamant Z; Bachert C
Allergy; 2016 Jul; 71(7):967-76. PubMed ID: 26864207
[TBL] [Abstract][Full Text] [Related]
19. Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial.
Wang DH; Chen L; Cheng L; Li KN; Yuan H; Lu JH; Li H
Laryngoscope; 2013 Jun; 123(6):1334-40. PubMed ID: 23616386
[TBL] [Abstract][Full Text] [Related]
20. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy.
Baron-Bodo V; Batard T; Nguyen H; Fréreux M; Horiot S; Harwanegg C; Bergmann KC; de Beaumont O; Moingeon P
Clin Exp Allergy; 2012 Oct; 42(10):1510-8. PubMed ID: 22994348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
